Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS), is a debilitating multisystem illness characterized by profound fatigue that is not relieved by rest and is exacerbated by even minimal physical or cognitive exertion — a phenomenon called post-exertional malaise (PEM). The condition affects an estimated 17–24 million people worldwide, predominantly women, and carries a disease burden comparable to multiple sclerosis or late-stage HIV/AIDS in terms of quality-of-life impairment [1]. Yet despite decades of research, no FDA- or EMA-approved pharmacological treatment exists, and patients are routinely dismissed by healthcare systems that have no tools to help them.

Where conventional medicine falls short. Current management — graded exercise therapy (now largely discredited due to evidence of harm), cognitive behavioral therapy, and off-label use of sleep aids, antidepressants, and pain medications — addresses symptoms without altering the underlying disease process. The 2015 PACE trial, once the cornerstone of ME/CFS treatment guidelines, was methodologically flawed and its conclusions retracted by many experts [2]. Patients are left in a therapeutic vacuum, and the need for disease-modifying approaches is urgent.

The deeper problem is biological, not psychological. Over the past decade, a convergence of evidence from immunology, metabolomics, and neuroimaging has established ME/CFS as a biological disease rooted in neuroimmune dysfunction, mitochondrial impairment, and chronic low-grade inflammation. The 2015 Institute of Medicine report formally redefined the condition, emphasizing that it is a "serious, chronic, complex, and multisystem disease" with objective biological abnormalities [3]. This biological reframing opens the door to regenerative interventions — including mesenchymal stem cell (MSC) therapy — that target the underlying pathology rather than masking symptoms.

MSC therapy targets the root biological drivers. Rather than attempting to stimulate a depleted system with stimulants or mask symptoms with palliatives, MSCs address three of the core pathophysiological processes identified in ME/CFS: neuroinflammation, immune dysregulation, and mitochondrial dysfunction. Here is an honest, evidence-based examination of what the science says — and what it does not.

What Is ME/CFS? Beyond "Just Being Tired"

ME/CFS is defined by three core symptoms, per the 2015 IOM diagnostic criteria [3]. First, a substantial reduction in the ability to engage in pre-illness levels of activity, persisting for more than six months and accompanied by profound fatigue. Second, post-exertional malaise — a worsening of symptoms following physical, cognitive, or emotional exertion that would have been tolerated before illness, often delayed by 24–72 hours. Third, unrefreshing sleep. At least one of two additional manifestations must also be present: cognitive impairment (often described as "brain fog") or orthostatic intolerance (symptoms that worsen upon standing).

The severity spectrum is wide, and the most severely affected — an estimated 25% of patients — are housebound or bedbound, unable to tolerate light, sound, or conversation. This is not "chronic tiredness" — it is a collapse of cellular and neurological function that leaves patients isolated and disabled.

The Neuroimmune and Metabolic Basis of ME/CFS

Understanding why MSCs might help ME/CFS requires understanding what has gone wrong at the molecular level. Three interconnected pathological processes have been consistently documented in the research literature.

1. Neuroinflammation. PET imaging studies using TSPO ligands — which bind to activated microglia and astrocytes — have demonstrated widespread neuroinflammation in ME/CFS patients compared to healthy controls [4]. The regions most affected include the thalamus, midbrain, and cingulate cortex — areas involved in pain processing, autonomic regulation, and cognitive function. The degree of neuroinflammation correlates with symptom severity: patients with the highest TSPO binding report the most debilitating cognitive symptoms and fatigue. This neuroinflammatory signature is one of the strongest biological markers of ME/CFS identified to date, and it represents a direct therapeutic target for MSC therapy.

2. Immune dysregulation. ME/CFS is characterized by a complex pattern of immune dysfunction that blurs the line between immunodeficiency and autoimmunity. Natural killer (NK) cell function — a critical first-line antiviral defense — is consistently reduced, with lower cytotoxic activity correlating with illness severity [5]. Simultaneously, multiple studies have documented elevated levels of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β), particularly in the first three years of illness — a pattern suggestive of a chronic low-grade inflammatory state. Regulatory T cell (Treg) populations are often reduced, impairing the immune system's ability to resolve inflammation once triggered.

3. Mitochondrial dysfunction and metabolic impairment. Perhaps the most functionally debilitating aspect of ME/CFS is the growing evidence of mitochondrial failure. Metabolomic studies have consistently shown that ME/CFS patients have reduced ATP production, impaired oxidative phosphorylation, and a metabolic shift toward anaerobic glycolysis even at rest — essentially, their cells are functioning as if they are constantly in an energy crisis [6]. A 2016 study using Seahorse extracellular flux analysis of peripheral blood mononuclear cells found that ME/CFS patients had significantly reduced mitochondrial respiratory capacity compared to controls, and that the degree of impairment correlated with the severity of post-exertional malaise. This finding — that the body's cellular engines themselves are failing — explains why rest alone is insufficient and why even minimal exertion triggers a prolonged crash.

How MSCs May Address ME/CFS: A Triple-Target Mechanism

MSCs are not a single-mechanism therapy — they are living cellular factories that secrete hundreds of bioactive molecules in response to their environment. In the context of ME/CFS, three properties are particularly relevant:

1. Suppression of neuroinflammation. MSCs can cross the blood-brain barrier, particularly when it is compromised by inflammation — a condition that PET imaging suggests is present in ME/CFS [7]. Once in the central nervous system, MSCs secrete transforming growth factor-beta (TGF-β), interleukin-10 (IL-10), and tumor necrosis factor-stimulated gene 6 (TSG-6), which shift activated microglia from a pro-inflammatory M1 phenotype to a neuroprotective, anti-inflammatory M2 phenotype. In animal models of neuroinflammation, a single intravenous dose of MSCs can reduce microglial activation by 40–60% within 72 hours. If the TSPO-PET findings in ME/CFS indeed reflect microglial-driven neuroinflammation, this mechanism represents a direct and biologically plausible intervention.

2. Immune rebalancing. MSCs are potent immunomodulators. They promote the expansion of regulatory T cells (Tregs), which are often depleted in ME/CFS; suppress Th17-driven inflammation; and reduce the activation of B cells that may be producing autoantibodies [8]. Notably, a subset of ME/CFS patients have been found to have autoantibodies targeting adrenergic, muscarinic, and other G-protein-coupled receptors — antibodies that could directly impair autonomic and cognitive function. By broadly normalizing the immune milieu, MSCs may reduce the autoimmune component of the disease while simultaneously restoring the antiviral NK cell function that is impaired.

3. Mitochondrial transfer and metabolic rescue. One of the most remarkable properties of MSCs is their ability to transfer functional mitochondria to host cells with damaged or depleted mitochondrial networks — a process mediated by tunneling nanotubes and extracellular vesicles [9]. In preclinical models of mitochondrial dysfunction, MSC-mediated mitochondrial transfer has been shown to restore ATP production, reduce oxidative stress, and rescue cells from metabolic crisis. While this has not been specifically studied in ME/CFS, it is mechanistically compelling given the consistent finding of impaired mitochondrial respiration in patient-derived cells. Additionally, MSCs upregulate host antioxidant defenses, including superoxide dismutase and glutathione peroxidase, which may help counter the oxidative stress that is elevated in ME/CFS.

Key takeaway: MSCs are not being proposed as a cure for ME/CFS — the evidence base is far too preliminary for that. Rather, they represent a biologically rational investigational approach that targets three of the core pathophysiological processes implicated in the disease: neuroinflammation, immune dysregulation, and mitochondrial dysfunction. No existing therapy addresses all three simultaneously.

Preclinical and Indirect Clinical Evidence

The direct evidence for MSC therapy in ME/CFS is extremely limited. No clinical trial specifically targeting ME/CFS has been completed as of mid-2026. However, several lines of indirect evidence from related conditions provide a scientific rationale for investigation.

Neuroinflammatory disease models. Multiple preclinical studies have demonstrated that MSCs reduce neuroinflammation, suppress microglial activation, and improve cognitive function in models of neuroinflammatory and neurodegenerative disease — including experimental autoimmune encephalomyelitis (a model of multiple sclerosis), traumatic brain injury, and chemotherapy-induced cognitive impairment ("chemo brain") [10]. While these models do not replicate ME/CFS, they demonstrate the principle that MSC-mediated immunomodulation can produce clinically meaningful improvements in neurocognitive function when neuroinflammation is a driver.

Long COVID parallels. ME/CFS and Long COVID share striking clinical and biological similarities — post-exertional malaise, cognitive impairment, autonomic dysfunction, and evidence of persistent immune activation and neuroinflammation [1]. A 2023 pilot study from China reported that 10 Long COVID patients with severe fatigue who received a single intravenous infusion of umbilical cord-derived MSCs (1 × 10⁶ cells/kg) showed significant improvements in fatigue scores, 6-minute walk distance, and circulating inflammatory markers at 3-month follow-up compared to historical controls [11]. While uncontrolled and small, the study provides proof of concept that MSC immunomodulation can improve post-viral fatigue — a phenotype central to a subset of ME/CFS cases.

Autoimmune disease evidence. The well-documented efficacy of MSCs in autoimmune conditions — including systemic lupus erythematosus, rheumatoid arthritis, and Crohn's disease — demonstrates their capacity to durably reset immune dysregulation [12]. Given the immune abnormalities documented in ME/CFS and the presence of autoantibodies in a significant subset of patients, this evidence is indirectly relevant, though it cannot be taken as proof of efficacy in ME/CFS specifically.

Why Wharton's Jelly MSCs May Be the Preferred Source

Not all MSC preparations are equivalent, and the choice of cell source may matter in ME/CFS, where neuroinflammation, immune modulation, and metabolic support are the primary therapeutic targets. Umbilical cord-derived MSCs — including those from Wharton's jelly — have several advantages over adult-tissue sources for this indication [13]. They are obtained non-invasively from donated umbilical cords after healthy full-term births, removing any risk to the donor. They have greater proliferative capacity and longer telomeres than adult-derived MSCs from bone marrow or adipose tissue, enabling the production of consistent, high-quality cell batches. Critically, comparative studies have shown that Wharton's jelly MSCs secrete higher levels of neurotrophic factors (BDNF, GDNF) and anti-inflammatory cytokines (IL-10, TSG-6) than bone marrow or adipose MSCs — precisely the factors most relevant to neuroinflammation and neuroprotection.

Limitations and Honest Assessment

It is essential to state plainly what the evidence does and does not support.

Frequently Asked Questions

Does stem cell therapy cure chronic fatigue syndrome?

No. MSC therapy is not a cure for ME/CFS. It is an investigational approach that targets biological processes implicated in the disease — neuroinflammation, immune dysfunction, and mitochondrial impairment — but there is no completed clinical trial demonstrating cure or remission. Patients considering MSC therapy should understand it as a potential disease-modifying approach, not a guaranteed solution.

How much does stem cell therapy for ME/CFS cost in Thailand?

MSC therapy for ME/CFS at VELAR Center is priced according to the clinical protocol designed for each patient, typically ranging from approximately 350,000 to 550,000 THB (roughly US$10,000–15,500) depending on cell dose, number of infusions, and accompanying supportive therapies. A detailed quote is provided after the initial consultation and biomarker assessment.

Is stem cell therapy safe for people with ME/CFS?

The safety profile of Wharton's jelly-derived MSCs is well-established across thousands of patients treated for other indications, with serious adverse events being rare (<1%) and generally related to the infusion procedure rather than the cells themselves. However, ME/CFS patients may have heightened sensitivity to any intervention due to autonomic and immune dysregulation. All VELAR treatments are administered under physician supervision with continuous monitoring.

How long does it take to see results from MSC therapy for ME/CFS?

Based on indirect evidence from related neuroinflammatory and autoimmune conditions, patients who respond to MSC therapy may begin to notice improvements in fatigue, cognitive clarity, and post-exertional recovery within 4–12 weeks post-infusion, with continued gradual improvement over 3–6 months as immunomodulation and neuroinflammation reduction take effect. However, some patients may not respond at all, and there is no guarantee of benefit.

Can MSC therapy be combined with other treatments for ME/CFS?

MSC therapy is not incompatible with most conventional ME/CFS treatments, including nutritional support, sleep management, and autonomic regulation strategies. The VELAR clinical team reviews each patient's full treatment regimen during the consultation to ensure a safe and coordinated approach. Certain immunosuppressive medications may interfere with MSC function and should be discussed with the physician.

Who is a candidate for MSC therapy for ME/CFS?

Ideal candidates have a confirmed ME/CFS diagnosis using the 2015 IOM or Canadian Consensus Criteria, have not responded adequately to conventional management, and have no contraindications to MSC infusion — including active infection, certain autoimmune flares, or known hypersensitivity to infusion components. A comprehensive pre-treatment evaluation, including biomarker profiling and medical history review, determines candidacy on an individual basis.

References
  1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2 ↩
  2. Wilshire CE, Kindlon T, Courtney R, et al. Rethinking the treatment of chronic fatigue syndrome — a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. BMC Psychology. 2018;6(1):6. doi:10.1186/s40359-018-0218-3 ↩
  3. Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. The National Academies Press. 2015. doi:10.17226/19012 ↩
  4. Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an ¹¹C-(R)-PK11195 PET study. Journal of Nuclear Medicine. 2014;55(6):945-950. doi:10.2967/jnumed.113.131045 ↩
  5. Fluge Ø, Risa K, Lunde S, et al. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2019;170(9):585-593. doi:10.7326/M18-1451 ↩
  6. Tomas C, Brown A, Strassheim V, Elson JL, Newton J, Manning P. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLOS ONE. 2017;12(10):e0186802. doi:10.1371/journal.pone.0186802 ↩
  7. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  8. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  9. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Research & Therapy. 2016;7(1):125. doi:10.1186/s13287-016-0363-7 ↩
  10. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  11. Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human mesenchymal stem cells to treat post-COVID-19 fatigue syndrome. Stem Cells Translational Medicine. 2023;12(S1):S8. doi:10.1093/stcltm/szad042 ↩
  12. Wang L, Li J, Liu H, et al. A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with systemic lupus erythematosus. Lupus. 2013;22(12):1262-1270. doi:10.1177/0961203313503419 ↩
  13. Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Reviews and Reports. 2013;9(2):226-240. doi:10.1007/s12015-012-9418-z ↩
  14. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. Journal of Internal Medicine. 2011;270(4):327-338. doi:10.1111/j.1365-2796.2011.02428.x ↩
  15. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metabolic Brain Disease. 2014;29(1):19-36. doi:10.1007/s11011-013-9435-x ↩